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Introduction: Hypercalcemia of malignancy (HCM) portends a very poor prognosis, and no established
guidelines exist regarding its management. Most instances of HCM are due to local osteolysis or secretion
of parathyroid hormone related-peptide, while less than 1% of all cases are due to ectopic secretion of
parathyroid hormone.
Case Report: We present an unusual case of HCM due to proposed cosecretion of both parathyroid hormone
and parathyroid hormone-related protein in a 36-year-old man with a poorly differentiated lung adenocarcinoma. The patient’s hypercalcemia was refractory to conventional measures, including intravenous
bisphosphonate therapy (zoledronic acid), and was improved with administration of denosumab.
Conclusion: This is the youngest and ﬁrst case of hypercalcemia of malignancy attributed to cosecretion
of PTH and PTHrP from an adenocarcinoma. In refractory cases of HCM, denosumab is a potential option
when other conventional measures are unsuccessful.
Published by Elsevier Inc. on behalf of the AACE. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
We describe an interesting case of severe refractory hypercalcemia attributed to ectopic production of parathyroid hormone
(PTH) and humoral hypercalcemia of malignancy in a young patient
with poorly differentiated lung adenocarcinoma. Differential diagnoses of concurrent elevated PTH and parathyroid hormonerelated peptide (PTHrP) are also discussed.
Case Report
Case Presentation
A 36-year-old man with stage IV poorly differentiated lung
adenocarcinoma with known brain metastases presented to our
Abbreviations: 1,25 vitamin D, 1,25-dihydroxy vitamin D; HCM, hypercalcemia
of malignancy; HD, hospital day; PTH, parathyroid hormone; PTHrP, parathyroid
hormone-related peptide; ZA, zoledronic acid.
* Address correspondence and reprint requests to Dr. Jeffrey M. Kroopnick, Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of
Medicine, 827 Linden Avenue, Baltimore, MD 21201.
E-mail address: jkroopnick@som.umaryland.edu (J.M. Kroopnick).

hospital with lethargy and a fall. On admission he had a severely
elevated serum calcium of 21.3 mg/dL (ref 8.9-10.3) and an ionized
calcium of 2.72 mmol/L (ref 1.0-1.25). His serum phosphorus was
low at 1.3 mg/dL (ref 2.4-4.7), serum creatinine was 1.30 mg/dL (ref
0.64-1.27), and his electrocardiogram showed a shortened corrected QT interval. Three weeks prior to admission, his calcium was
normal, ranging from 8.7 to 9.5 mg/dL, and approximately 10 days
prior to admission his renal function was normal (creatinine 0.79),
and he received his ﬁrst round of chemotherapy. He initially
received aggressive intravenous ﬂuid hydration, calcitonin, and
doses of zoledronic acid (ZA) on hospital day (HD) #1 and #9 (4 mg
IV). After his ﬁrst dose of ZA, his nadir calcium was 11.0 mg/dL on
HD#7 but then rose to 12.8 mg/dL before receiving a second dose
on HD#9. Further workup revealed elevated PTH levels of 33.2,
55.4, and 133.0 pmol/L (ref 1.3-6.8) on HD#2, 6, and 9, respectively.
He had a reduced 25-hydroxvitamin D of 7 ng/mL (ref 25-80) and
1,25-dihydroxy vitamin D (1,25 vitamin D) of 14 pg/mL (ref 15-75),
both measured on HD#4. Interestingly, his PTHrP was elevated at
8.2 pmol/mL (ref 0-2.3) on HD#4. No parathyroid adenoma was
detected on magnetic resonance imaging neck, 99mTc-sestamibi
scan, or parathyroid ultrasound. Imaging revealed widespread
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normal after multiple doses of ZA in a patient with metastatic
intermediate-grade lymphoma, it is thought that this is related to
the hypocalcemia induced by osteoclast inhibition. In our case, ZA
was administered less than 24 hours prior to our patient’s ﬁrst PTH
measurement, and his degree of hyperparathyroidism, approximately 20 times the upper limit of normal, is thus not consistent
with that following antiresorptive therapy, especially given our
patient was persistently hypercalcemic following only 1 dose of ZA.
Therefore, his HCM could be attributed to 3 likely mechanisms:
local osteolysis, PTHrP, and ectopic PTH cosecretion.
PTHrP resembles the N-terminal sequence of PTH and thus can
bind to the type 1 PTH receptor. Given this, PTHrP can increase
renal tubular reabsorption of calcium, increase renal urinary
excretion of phosphorus, and also increase expression of receptor
activator of nuclear factor kappa-B ligand on osteoblasts. However,
unlike PTH, PTHrP does not increase 1,25 vitamin D levels, so
enhanced reabsorption of intestinal calcium and phosphorus does
not occur.8 This, in conjunction with his vitamin D deﬁciency, likely
explains our patient’s low 1,25 vitamin D. Only 1 of the reported
cases of cosecretion of PTH and PTHrP measured the 1,25 vitamin D
level,5 which was low, and our case also documents the predominant effect of PTHrP on 1,25 vitamin D regulation. While the pathology available from his craniotomy did not stain positive for PTH,
it is unclear if all tumor cells gain the ability to cosecrete both
hormones or if clonal heterogeneity exists. Our patient had widespread metastatic disease, which was not evaluated pathologically
and could account for the ectopic PTH production.
No consensus guidelines exist for the management of HCM, but
a standard approach involves cessation of any medications that
may promote hypercalcemia, ambulation to prevent immobility,
intravenous ﬂuids, and antiresorptive therapy. Pharmacologic options include subcutaneous or intravenous calcitonin and intravenous bisphosphonates to inhibit osteoclast resorption.9,10
Calcitonin lowers serum calcium levels within hours, but its use
is limited to 48 to 72 hours due to tachyphylaxis.10,11 The intravenous bisphosphonate ZA can take up to 2 days to exert its effects.11
These are temporizing measures to allow time for management of
the underlying malignancy with systemic therapy, radiation, and/or
surgery. Glucocorticoids are ﬁrst-line treatment in calcitriolmediated hypercalcemia; our patient received dexamethasone
prior to admission and development of hypercalcemia. Given the
patient’s known brain metastases, he remained on dexamethasone
throughout his hospital course. Despite the patient having received
all of the aforementioned measures, his calcium failed to remain
normal.
Retreatment with ZA in HCM may be as frequent as every 3 to 4
weeks. However, in our case, there was rebound hypercalcemia 8
days following the ﬁrst administration of ZA, and the patient’s
calcium did not normalize following the second dose, all in the
setting of deteriorating mental status (Fig. 1). Resistance to
bisphosphonates may occur in humoral HCM because bisphosphonates are unable to inhibit PTHrP-induced calcium reabsorption in
the kidneys.3
Studies suggest that denosumab, a monoclonal antibody that
inhibits the signaling of receptor activator of nuclear factor kappa-B
ligand , a key factor for osteoclast differentiation and activation,
provides beneﬁt in cases of bisphosphonate-refractory hypercalcemia.12,13 The calcimimetic agent, cinacalcet, is approved for
treatment of both benign parathyroid disorders and parathyroid
carcinoma. There are 2 reports in the literature on the use of
cinacalcet for a tumor producing ectopic PTH.2,14 Asonitis et al3
described a patient with HCM due to metastatic estrogen receptor positive mammary carcinoma, with peak serum calcium of 14
mg/dL and poorly responsive to aggressive ﬂuid hydration, furosemide, calcitonin, ZA, and denosumab. Cinacalcet was added in

Fig. 1. Tissue from a brain metastasis resected a month prior to admission, showing
positive nuclear staining for PTHrP (dark brown). Parafﬁn sections were dewaxed,
rehydrated, and antigen retrieval was performed in 10 mM sodium citrate, pH 6.0, for
10 minutes using an electric pressure cooker. Sections were cooled, blocked with 3%
hydrogen peroxide, then for endogenous biotin (Biocare Medical Kit #AB972), and
incubated with 10% goat serum. Rabbit polyclonal antibody to PTHrP (sc-20728; Santa
Cruz Biotechnology, Santa Cruz, CA) was used at 1:200 with overnight incubation at
4oC. PTHrP antibody binding was detected using the Vectastain Elite ABC HRP Kit
(Vector Labs, Burlingame, CA) and developed with Dako Liquid DAB substrate (Dako
Corp, Carpinteria, CA). PTHrP ¼ parathyroid hormone-related peptide.

abdominal metastases and small lytic lesions. Pathology from his
craniotomy stained negative for PTH but positive for PTHrP (Fig. 1).
He also received one dose of denosumab, 120 mg on HD#12, after
which his serum calcium normalized. However the patient elected
for hospice care and expired. Figure 2 illustrates the patient’s calcium trend and the various interventions he received during his
hospitalization.
Discussion
Hypercalcemia of malignancy (HCM) portends a very poor
prognosis and is an oncologic emergency that can occur in 10% to
20% of adult patients with cancer.1
The Table summarizes the multiple mechanisms of HCM,
including local osteolysis, humoral hypercalcemia of malignancy
(ie, PTHrP), calcitriol, and ectopic PTH secretion.2 More speciﬁcally,
tumor cells in bone secrete cytokines and growth factors that
stimulate release of receptor activator of nuclear factor kappa-B
ligand from osteoblasts, which activates osteoclasts. Secondly,
bone resorption itself may promote release of growth factors that
lead to tumor growth and enhanced survival. PTHrP secreted by
tumor cells mimic PTH by binding the common PTH/PTHrP receptor to increase bone resorption and renal calcium retention.1,3
To our knowledge, only 3 case reports exist of patients with
cosecretion of PTH and PTHrP. These patients were all at least 70
years of age and had either gastric, squamous cell, or transitional
cell carcinomas.4e6 Imaging and/or autopsy revealed no abnormal
or ectopic parathyroid tissue.4e6 Our patient’s acute onset and severe degree of hypercalcemia in the setting of a lack of abnormal
parathyroid tissue on imaging is most consistent with a paraneoplastic process. The degree of PTH elevation could not be solely
related to known causes of secondary hyperparathyroidism,
including vitamin D deﬁciency, administration of antiresorptive
agents, or his minimally reduced glomerular ﬁltration rate. While
ZA has been purported to cause a mild secondary hyperparathyroidism, as mentioned in a case report from Sayn and Yazici,7 in
which the PTH was approximately 4 times the upper limit of
201
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Fig. 2. Time course of serum calcium levels prior to and in response to different treatments during hospitalization. The serum calcium trend is illustrated graphically with the
various treatment measures the patient received throughout. Please note that the patient received doses of calcitonin on HD#10, 11, 12, 14, and 15, which are not represented in this
ﬁgure. HD ¼ hospital day.

Table
Overview of the Mechanisms and Frequency of Hypercalcemia of Malignancy
Causes

Local osteolysis

Calcitriol (1,25-[OH]2 vitamin D)

PTHrP

Ectopic PTH

Types of malignancy

Breast, lung, myeloma, renal

Lymphoid tumors

Lung, ovarian, pancreatic,
thyroid, transitional cell

Frequency
mechanism of action

20%
Cytokines and/or chemokines
leading to calcium release
from bone
PTH low
PTHrP normal
1,25-(OH)2 vitamin D variable

<1%
Acts on bowel and kidneys to absorb
and reabsorb calcium, respectively

Breast, bladder, ovarian, renal,
squamous cell,
non-Hodgkin lymphoma
80%
Renal reabsorption of calcium,
osteoclast stimulation

Expected
laboratory data

Pharmacologic options

Bisphosphonate denosumab

PTH low
Phosphorus high
PTHrP normal
1,25-(OH)2 vitamin D high
Glucocorticoids

PTH low
PTHrP high
1,25-(OH)2 vitamin D low

<1%
Acts on 1-a hydroxylase in kidney,
stimulates osteoclasts
(calcium release)
PTH high
PTHrP normal
1,25-(OH)2 vitamin D high

Bisphosphonate denosumab

Bisphosphonate denosumab

Abbreviations: PTH ¼ parathyroid hormone; PTHrP ¼ parathyroid hormone-related peptide.
Note: Adapted from reference 2.

applicable in our case, PTH values in the setting of humoral hypercalcemia of malignancy are normal or high-normal.20,21
While we realize that the cosecretion of PTH and PTHrP leading
to hypercalcemia is an unusual and rare event, our patient’s PTH
would not be explained by primary or secondary hyperparathyroidism. Clonal heterogeneity may be a limiting factor for pathologic conﬁrmation of ectopic PTH secretion. The acuity and degree
of hypercalcemia and hyperparathyroidism without imaging
conﬁrmation of a parathyroid lesion, together with an elevated
PTHrP value, make primary hyperparathyroidism very unlikely.
Further, the magnitude of his hyperparathyroidism is not consistent
with that seen secondary to vitamin D deﬁciency, prolonged renal
impairment, or administration of therapy to inhibit osteoclast
function. This case underscores the importance of measuring a PTH
value even in patients with acute-onset hypercalcemia in the
setting of known malignancy. Doing so may yield increased

addition to monthly denosumab, and her serum calcium normalized to 9.6 mg/dL approximately 4 weeks after initiation of the
calcimimetic. A dose of denosumab, 120 mg, which has a median
time to response of 9 days,10 was administered to our patient on
HD#12 with improvement of his serum calcium.
Rare cases of primary hyperparathyroidism due to an adenoma
with hypercalcemia of malignancy have been reported, but while
the PTH is not suppressed, this degree of elevation is atypical unless
there is parathyroid cancer; further, these patients had imaging
conﬁrmation of a parathyroid adenoma.15e17 Moreover, >90% of
patients with primary hyperparathyroidism have undetectable
levels of PTHrP and, even further, the speciﬁc detection of PTH has
been signiﬁcantly enhanced due to the 2-site radioimmunoassay, so
cross-reactivity with PTHrP is minimized, if not absent.15,16,18,19
Outside of parathyroid carcinoma in multiple endocrine neoplasia
1 or in tertiary hyperparathyroidism, both of which were not
202
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detection of ectopic PTH production. That being said, management
is challenging and it remains unclear if these patients may be more
resistant to traditional therapeutic measures. Early recognition of
the causes of HCM and its various treatment options are important
to optimize patient management.
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Conclusion
This is the youngest and ﬁrst case of hypercalcemia of malignancy due to cosecretion of PTH and PTHrP from an adenocarcinoma. Denosumab is a potential option to treat refractory
hypercalcemia of malignancy when other conventional measures
are unsuccessful.
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